Hereditary Angioedema Soft tissue swelling
Conditions
Interventions
None listed
Sponsors
Intellia Therapeutics INC.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Participant has completed follow-up in the ITL-2002-CL-001 clinical trial and received a dose of at least 50 mg NTLA-2002 at any point during the trial • Participant is enrolled in the long-term follow-up observational study ITL-2002-CL999 (LTFU) • Participant was enrolled at a clinical trial site located in Australia, New Zealand, the Netherlands, Germany, or the UK • Participant is fluent in English (Australia, New Zealand, the UK), German (Germany) or Dutch (the Netherlands) • Participant provides informed consent • Participant is willing and able to participate in one 60-minute, telephone- or web conference- based interview by an ICON or ICON trained interviewer, native speaker of local language • Participant is willing to be audio recorded • Participant is willing to be contacted by a third party for interview purposes
Exclusion criteria
Exclusion criteria: • Participant is unwilling or unable to comply with study procedures • Ongoing participation in an interventional clinical trial with NTLA-2002, excluding observational long-term follow up ITL-2002-CL-999 study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Participants treated in the above clinical trials will be interviewed to further characterize the impact of the onetime treatment on disease elements beyond attack-rates, including psychosocial burden of disease and treatment burden. | — |
Countries
Australia, Germany, Netherlands, New Zealand, United Kingdom
Contacts
Public ContactC Morandin
ICON Clinical Research
Outcome results
None listed